UH, Baylor researchers make breakthrough with new pediatric leukemia treatment device

childhood cancer

Researchers from Baylor College of Medicine and the University of Houston have developed a new blood-filtering machine that poses fewer risks to pediatric patients with hyperleukocytosis. Photo courtesy UH.

A team of Houston researchers has developed a new microfluidic device aimed at making treatments safer for children with hyperleukocytosis, a life-threatening hematologic emergency often seen in patients with leukemia.

Dr. Fong Lam, an associate professor of pediatrics at Baylor College of Medicine and a pediatric intensive care physician at Texas Children’s Hospital, partnered with Sergey Shevkoplyas, a professor of biomedical engineering at UH, on the device that uses a large number of tiny channels to quickly separate blood cells by size in a process called controlled incremental filtration, according to a news release from UH.

They tested whether performing cell separation with a high-throughput microfluidic device could alleviate the limitations of traditional conventional blood-filtering machines, which pose risks for pediatric patients due to their large extracorporeal volume (ECV), high flow rates and tendency to cause significant platelet loss in the patient. The results of their study, led by Mubasher Iqbal, a Ph.D. candidate in biomedical engineering at UH, were published recently in the journal Nature Communications.

“Continuously and efficiently separating leukocytes from recirculating undiluted whole blood — without device clogging and cell activation or damage — has long been a major challenge in microfluidic cell separation,” Shevkoplyas said in a news release. “Our study is the first to solve this problem.”

Hyperleukocytosis is a condition that develops when the body has an extremely high number of white blood cells, which in many cases is due to leukemia. According to the release, up to 20 percent to 30 percent of patients with acute leukemia develop hyperleukocytosis, and this places them at risk for potentially fatal complications.

The new device utilizes tiny channels—each about the width of a human hair—to efficiently separate blood cells through controlled incremental filtration. According to Lam, the team was excited that the new device could operate at clinically relevant flow rates.

The device successfully removed approximately 85 percent of large leukocytes and 90 percent of leukemic blasts from undiluted human whole blood without causing platelet loss or other adverse effects. It also operates with an ECV that’s about 1/70th of conventional leukapheresis machines, which makes it particularly suitable for infants and small children.

“Overall, our study suggests that microfluidics leukapheresis is safe and effective at selectively removing leukocytes from circulation, with separation performance sufficiently high to ultimately enable safe leukapheresis in children,” Shevkoplyas said in the release.

From Your Site Articles
A team of researchers at the University of Houston is working to develop a new treatment for Rhabdomyosarcoma, an aggressive cancer with a higher incidence in young children. Photo via Getty Images.

UH research team receives grant to fight aggressive pediatric cancer

cancer research

Researchers at the University of Houston have received a $3.2 million grant from the National Institutes of Health to help find innovative ways to treat Rhabdomyosarcoma, or RMS.

According to a statement from the university, RMS is a malignant soft tissue sarcoma that has a higher incidence in young children and is responsible for 8 percent of pediatric cancer cases with a relatively low survival rate.

One way UH is working on the issue is by studying how and why RMS cells, which are found most often in muscle tissue, divide uncontrollably without ever maturing into normal muscle cells. The researchers aim to tackle a target inside RMS cells known as TAK1, which plays a key role in regulating cell growth.

“By targeting TAK1, we aim to stop the cancer at its source and help the cells develop normally,” Ashok Kumar, the Else and Philip Hargrove Endowed Professor of Drug Discovery at the UH College of Pharmacy and director of the Institute of Muscle Biology and Cachexia, said in a news release. “This approach could lead to new and better treatments for RMS.”

According to UH, preliminary results demonstrated that TAK1 is highly activated in embryonal RMS cells, which are found in younger children; alveolar RMS cells, which are found in older children and teens; and human RMS samples. This suggests that the protein plays a major role in the development of this form of cancer.

The team still aims to uncover how the protein helps RMS cancer grow and plans to evaluate how blocking TAK1 can be used as a therapeutic.

“Blocking TAK1, either by changing the genes (genetic approaches) or using drugs (pharmacological approaches), can stop certain harmful behaviors in cancer cells,” Kumar added. “This was tested both in lab-grown cells and in living models, showing that TAK1 is a key target to control RMS cancer’s spread and aggressiveness, and inhibits tumor formation.”

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Houston biotech startup raises millions to battle pediatric cancer

fresh funds

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice University lands $14M state grant to open Center for Space Technologies

on a mission

Rice University’s Space Institute soon will be home to the newly created Center for Space Technologies.

On Feb. 17, the Texas Space Commission approved a nearly $14.2 million grant for the Rice project. The Center for Space Technologies will target:

  • Research and development
  • Technology transfer and innovation
  • Statewide partnerships
  • Workforce development training
  • Space-focused education programs

The goal of the new center “is to fulfill an articulated need for research, workforce development, and industry collaboration,” said Kemah communications and marketing executive Gwen Griffin, chair of the commission.

State Rep. Greg Bonnen, a Friendswood Republican, authored the bill that set up the Texas Space Commission.

Since being authorized in 2023, the commission has funded 24 projects, with Rice and Houston-area companies accounting for nearly $75 million in grants to back space-related initiatives.

The grant to Rice brings the TSC's total investment to $150 million, fully committing the entire state appropriation from the Texas Legislature in 2023.

Other local companies that have received grants over the years include Aegis Aerospace, Axiom Space, Intuitive Machines, Starlab Space and Venus Aerospace.

The commission also awarded $7 million to Blue Origin earlier this month. See a list of the 24 awards here.

Waymo self-driving robotaxis have officially launched in Houston

Waymo has arrived

Waymo will begin dispatching its robotaxis in four more cities in Texas and Florida, expanding the territory covered by its fleet of self-driving cars to 10 major U.S. metropolitan markets.

The move into Dallas, Houston, San Antonio and Orlando, Florida, announced Tuesday, February 24, widens Waymo's early lead in autonomous driving while rival services from Tesla and the Amazon-owned Zoox are still testing their vehicles in only a few U.S. cities.

In contrast, Waymo's robotaxis already provide more than 400,000 weekly trips in the six metropolitan areas where they have been transporting passengers: Phoenix, the San Francisco Bay Area, Los Angeles, Miami, Atlanta, and Austin, Texas.

Waymo operates its ride-hailing service through its own app in all the U.S. cities except Atlanta and Austin, where its robotaxis can only be summoned through Uber's ride-hailing service.

The expansion into four more markets marks a significant step toward Waymo's goal to surpass 1 million weekly paid trips by the end of 2026. Without identifying where its robotaxis will be available next, Waymo is targeting a list of eight other cities that include Las Vegas, Washington, Detroit and Boston while signaling its first overseas availability is likely to be London.

To help pay for more robotaxis, Waymo recently raised $16 billion as part of the financial infusion that puts the value of the company at $126 billion. The valuation fueled speculation that Waymo may eventually be spun off from its corporate parent Alphabet, where it began as a secret project within Google in 2009.

Although Waymo is opening up in four more cities, its robotaxis initially will only be made available to a limited number of people with its ride-hailing app in Dallas, Houston, San Antonio and Orlando before the service will be available to all comers in those markets.

Tech giant Apple doubles down on Houston with new production facility

coming soon

Tech giant Apple announced that it will double the size of its Houston manufacturing footprint as it brings production of its Mac mini to the U.S. for the first time.

The company plans to begin production of its compact desktop computer at a new factory at Apple’s Houston manufacturing site later this year. The move is expected to create thousands of jobs in the Houston area, according to Apple.

Last year, the Cupertino, California-based company announced it would open a 250,000-square-foot factory to produce servers for its data centers in the Houston area. The facility was originally slated to open in 2026, but Apple reports it began production ahead of schedule in 2025.

The addition of the Mac mini operations at the site will bring the footprint to about 500,000 square feet, the Houston Chronicle reports. The New York Times previously reported that Taiwanese electronics manufacturer Foxconn would be involved in the Houston factory.

Apple also announced plans to open a 20,000-square-foot Advanced Manufacturing Center in Houston later this year. The project is currently under construction and will "provide hands-on training in advanced manufacturing techniques to students, supplier employees, and American businesses of all sizes," according to the announcement. Apple opened a similar Apple Manufacturing Academy in Detroit last year.

Apple doubles down on Houston with new production facility, training center Photo courtesy Apple.

“Apple is deeply committed to the future of American manufacturing, and we’re proud to significantly expand our footprint in Houston with the production of Mac mini starting later this year,” Tim Cook, Apple’s CEO, said in the news release. “We began shipping advanced AI servers from Houston ahead of schedule, and we’re excited to accelerate that work even further.”

Apple's Houston expansion is part of a $600 billion commitment the company made to the U.S. in 2025.

View All Listings